Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day - Pharming (NASDAQ:PHAR)

Summary by Benzinga
Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone

1 Articles

BenzingaBenzinga
Center

Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day - Pharming (NASDAQ:PHAR)

Highlights advancing clinical-stage pipeline, including two major value-creating programs for primary immunodeficiencies (PIDs) with immune dysregulation and mtDNA-driven mitochondrial diseaseIntroduces napazimone

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Tuesday, February 3, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Leiden icon

Leiden

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal